NEWSWORTHY
Takeda moving U.S. HQ from Chicago area to Boston, affecting 1,000 workers
Japanese drugmaker Takeda says it is closing its U.S. headquarters in suburban Chicago with about 1,000 employees and moving its functions to the Boston area. Takeda spokeswoman Julia Ellwanger said Tuesday that the work currently performed at the offices in Deerfield, Illinois, will gradually shift ...
Takeda bets on China for global growth, seeing the country as 'on a par' with the U.S. and Europe
Takeda Pharmaceutical Co. sees China becoming a "core country" for its global growth strategy, and is optimistic its $62 billion (¥6.94 trillion) acquisition of Shire PLC will win approval by the country's regulators. Takeda is preparing to begin selling seven new drugs in China in ...
Takeda considers selling Osaka headquarters to fund Shire purchase
Takeda Pharmaceutical Co. is considering selling its symbolic Osaka headquarters building to help finance its £46 billion ($60 billion) deal to acquire Irish drugmaker Shire Plc., sources close to the matter said Friday. The building, located in the Doshomachi district in the city of Osaka, ...
Foreign mega-deals challenged by Fujifilm and Takeda shareholders
Fujifilm Holdings Corp. President Kenji Sukeno told shareholders on Thursday that the company will continue to pursue a merger with Xerox Corp. despite the U.S. printer and copier-maker's decision to terminate the deal. "It is the best option for Fuji Xerox and Xerox. I will ...
Challenges await Takeda after $62 billion Shire victory
Takeda Pharmaceutical Co.'s Chief Executive Officer Christophe Weber navigated rebuffs, critics and a plunging stock price to win a $62 billion (¥6.8 trillion) deal to acquire larger rival Shire Plc. Integrating the Japanese drugmaker — which began by selling herbal therapies 237 years ago — ...
Shire bid marks Takeda's latest and biggest push for global status
Takeda Pharmaceutical Co. Ltd..'s $64 billion bid for London-listed rare-disease specialist Shire PLC bolsters its credentials as Japan's most outward-facing drugs firm, a mold-breaking image that has been more than a decade in the making. Under CEO Christophe Weber and his predecessor, Yasuchika Hasegawa, Takeda ...
Takeda's $60 billion takeover bid rejected by Shire Group of Ireland
Pharmaceutical giant Takeda said Thursday it had made a takeover bid worth £42 billion ($60 billion) for Ireland's Shire Group, but that its offer was rejected. "Takeda was subsequently notified that the board of Shire had rejected its proposal. Discussions between the parties regarding a ...
Takeda shares slide amid $50 billion takeover bid for Shire
Shares of Takeda Pharmaceutical Co. fell the most in nine years after the firm disclosed it is considering a bid for Shire PLC that could approach $50 billion (about ¥5.3 trillion), which would be the Japanese company’s biggest takeover ever. The decline in early Tokyo ...
Takeda drug could be part of functional cure for HIV: study
Dr. Anthony Fauci doesn't get too excited about the results of animal studies, and he doesn't make house calls. But when a drug already taken by thousands of people for intestinal conditions appeared to control the monkey version of HIV, it got the attention of ...
U.S. regulators are greenlighting a new weight-loss drug called Contrave, the third in a string of approvals for anti-obesity treatments. The drug was developed by Orexigen Therapeutics Inc., based in La Jolla, California. The Food and Drug Administration said Thursday that it is approved for ...
Takeda Pharmaceutical to stay Japan-based while growing on global basis, new French leader vows
The inauguration in June of Christophe Weber as president of Takeda Pharmaceutical Co. invited opposition from a group of its former executives and members of its founding family, but the Frenchman says Takeda will remain "Japanese-based" under his leadership. "I think there is sometimes this ...
Christophe Weber, the new chief operating officer of Takeda Pharmaceutical Co., said Wednesday he aims to make the company the world's leading drugmaker by drawing on his more than two decades of business experience at GlaxoSmithKline. He said his ambition for Takeda is "being a ...
